Relationship between biological variation in B-type natriuretic peptide and plasma renin concentration in stable outpatients with dilated cardiomyopathy

Circulation Journal

Volumn 75, Issue 8, 2011, Pages 1897-1904

  Nishiyama, Keizo ^a   Tsutamoto, Takayoshi ^a   Kawahara, Chiho ^a   Yamaji, Masayuki ^a   Sakai, Hiroshi ^a   Yamamoto, Takashi ^a   Fujii, Masanori ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Biological variation; Brain natriuretic peptide; Dilated cardiomyopathy; Heart failure; Renin concentration

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; RENIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PLASMA RENIN ACTIVITY; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; BLOOD PRESSURE; BODY WEIGHT; CARDIOMYOPATHY, DILATED; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBSERVER VARIATION; OUTPATIENTS; PROSPECTIVE STUDIES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79960824157     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1083     Document Type: Article

References (35)

1. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
2. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999; 137: 352-360.
3. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735-1743.
4. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and aminoterminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528-1538.
5. Tanino Y, Shite J, Paredes OL, Shinke T, Ogasawara D, Sawada T, et al. Whole body bioimpedance monitoring for outpatient chronic heart failure follow up. Circ J 2009; 73: 1074-1079.
6. Packer M, Medina N, Yushak M, Lee WH. Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure: Experience in 100 consecutive patients. Br Heart J 1985; 54: 298-304.
7. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II: The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: 40-48.
8. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21: 53-57.
9. Ishikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 2006; 70: 857-863.
10. Tsutamoto T, Sakai H, Nishiyama K, Tanaka T, Fujii M, Yamamoto T, et al. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J 2007; 71: 1873-1878.
11. Moertl D, Hammer A, Huelsmann M, Pacher R, Berger R. Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients. Eur J Heart Fail 2008; 10: 404-411.
12. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-1283.
13. Bettencourt P, Frioes F, Azevedo A, Dias P, Pimenta J, Rocha- Goncalves F, et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 2004; 93: 45-48.
14. Yan RT, White M, Yan AT, Yusuf S, Rouleau JL, Maggioni AP, et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005; 96: 698-704.
15. Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, Moriguchi M, et al. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol 2008; 51: 2329-2335.
16. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Fujii M, Yamamoto T, et al. Biological variation of brain natriuretic peptide and cardiac events in stable outpatients with nonischemic chronic heart failure. Circ J 2011; 75: 341-347.
17. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008; 52: 997-1003.
18. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
19. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004; 50: 2052-2058.
20. Wu AH. Serial testing of B-type natriuretic peptide and NTpro- BNP for monitoring therapy of heart failure: The role of biologic variation in the interpretation of results. Am Heart J 2006; 152: 828-834.
21. Schou M, Gustafsson F, Kjaer A, Hildebrandt PR. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 2007; 28: 177-182.
22. Schou M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007; 9: 68-74.
23. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82.
24. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005; 123: 439-445.
25. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006; 47: 582-586.
26. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49: 1733-1739.
27. Tsutamoto T, Nishiyama K, Sakai H, Tanaka T, Fujii M, Yamamoto T, et al. Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 1208-1214.
28. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Prognosis of the relationship between the dose of carvedilol and transcardiac gradient of norepinephrine in patients with chronic heart failure. Circ J 2009; 25: 882-890.
29. Tsutamoto T, Sakai H, Tanaka T, Fujii M, Yamamoto T, Wada A, et al. Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure. Circ J 2007; 71: 915-921.
30. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: Extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1375-1382.
31. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003; 92: 628-631.
32. Takeda Y, Takeda Y, Suzuki S, Kimura G. Within-person variation of the plasma concentration of B-type natriuretic peptide: Safety range in stable patients with heart failure. Am Heart J 2009; 157: 97-101.
33. Lang CC, Coutie WJ, Khong TK, Choy AM, Struthers AD. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens 1991; 9: 779-782.
34. Kjaer A, Appel J, Hildebrandt P, Petersen CL. Basal and exerciseinduced neuroendocrine activation in patients with heart failure and in normal subjects. Eur J Heart Fail 2004; 6: 29-39.
35. Damgaard M, Goetze JP, Norsk P, Gadsboll N. Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy individuals and patients with compensated heart failure. Eur Heart J 2007; 28: 2726-2731.